A method of growing stable, long-term expandable human neural progenitor cell lines has been a priority for disease modeling and therapy of various neurological diseases. Here we discuss two projects with the need for a defined serum-free medium necessary for the expansion of both human neural progenitor cells derived from fetal cortex (hNPCs) and inducible pluripotent stem cells (iPSCs) derived from adult skin fibroblasts.
Speaker: Clive Svendsen, PhD
Published: Thursday, 03 February, 2011
Stem cell research is an exciting field that promises fantastic curative discoveries in numerous areas from cancer to diabetes to neurodegenerative diseases. As such, technologies that allow researchers to routinely and efficiently edit the genomes of stem cells from virtually any species, by directing mutations in a truly targeted fashion, would greatly enhance the understanding of basic stem cell biology and potentially lead to novel ways of treating human disease. There is an ongoing need for tools that support scientists in their discovery efforts to better understand the cellular processes controlling development, aging, disease, and tissue regeneration. To this end, we discuss today a novel technology that enables high frequency genome editing via the application of designed zinc finger nucleases (ZFNs).
Speaker: Bindu Joshi, PhD, Biotech Consultant Sigma-Aldrich
Published: Thursday, 30 September, 2010
Human somatic cells may be reprogrammed to an embryonic-like status by means of using induced pluripotent stem cell technology. These cells, commonly termed iPSCs, have resolved the ethical and practical concerns surrounding the human embryonic stem cell field in research applications. However the procedure is very inefficient and currently it is unclear which tissue of origin is better for performing the reprogramming. Here we describe the efficient generation of human iPSCs from seven different donor cell types (umbilical cord, amniotic mesenchymal, chorionic mesenchymal, amniocytes, adipose stem cells, periosteum, and skin fibroblasts). We will also discuss the potential advantages of choosing extraembryonic tissues as the starting population.
Speaker: Miguel Angel Esteban, PhD, Key Laboratory of Regenerative Biology, South China Institute for Stem cell Biology and Regenerative Medicine, Guangzhou Institute of Biomedicine and Health
Published: Thursday, 30 September, 2010
Three leading experts in iPS research discuss the current status of iPS cell technology with an emphasis on iPS methodology and use in research for human disease, drug screening and cell-based therapy.
Published: Thursday, 12 November, 2009
Since Yamanka et al first described generation of iPS cells in 2006, many variations to the reprogramming method have evolved to improve efficiency and safety for clinical applications. The webinar will cover important milestones since the original publication.
Speaker: Stephen Chang PhD, Chief Scientific Officer, Stemgent Inc
Published: Thursday, 07 January, 2010
The Stemgent® Lentivirus Reprogramming product line offers a broad selection of Dox-inducible and non-inducible reprogramming factors for mouse and human cells. The webinar covers validation and selection of reprogrammed cells as well as iPS colony morphology changes during reprogramming and how to identify which colonies to pick for expansion.
Speaker: Brad Hamilton, Sr. Scientist, Stemgent Inc
Published: Thursday, 07 January, 2010
Kyle Brueggeman, Product Manager, explains the expansion of the Your Favorite Gene Web site. We've added a biologically relevant literature search, new gene regulation and variation viewers, expression study results, clinical trials, detailed disease relationships, and biochemical compound interactions related to your gene of interest. Spend less time searching multiple sites and find it all in YFG. See what's new!
Published: Thursday, 29 April, 2010
A brief overview of epigenetic modifications and associated enzymes from Proteolysis.org
Published: Tuesday, 14 October, 2008
